Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Chronic Aphasia
Interventions: HD-tDCS (Soterix Medical, Active), HD-tDCS (Soterix Medical, Sham); Device
Lead sponsor: Soterix Medical; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Chapel Hill, North Carolina

Conditions: Treatment for Cellulite on the Stomach and Flanks
Interventions: Cutera truSculpt Device; Device
Lead sponsor: Cutera Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 3
States / cities: Sacramento, California • Glencoe, Illinois • New York, New York

Conditions: Hyperpronated Foot, Reconstruction Surgeries of the Foot, Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle, Fixation of Small Bone Fragments of the Foot/Ankle, Lisfranc Arthrodesis, Mono or Bi-cortical Osteotomies in the Forefoot, First Metatarsophalangeal Arthrodesis, Akin Osteotomy, Midfoot and Hindfoot Arthrodeses or Osteotomies, Fixation of Osteotomies for Hallux Valgus Treatment (Scarf and Chevron), Arthrodesis of the Metatarsocuneiform Joint to Reposition and Stabilize Metatarsus Primus Varus, Osteotomy Fixation of Hallux Valgus Repair (Such as Scarf and Chevron Etc.), Medial Ankle Stabilization, Tibiotalocalcaneal Arthrodesis
Interventions: Products listed in Group/Cohort Description; Device
Lead sponsor: Arthrex, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Sacramento, California • Chicago, Illinois • Nashville, Tennessee + 2 more

Conditions: Chronic Uveitis
Interventions: infliximab; Drug
Lead sponsor: Egla C. Rabinovich; Other
Eligibility: 4 Years to 18 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ALZT-OP1a (cromolyn); Drug
Lead sponsor: AZTherapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: La Jolla, California • Jacksonville, Florida • New York, New York + 2 more

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions: HCD122; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 5
States / cities: Chicago, Illinois • Beech Grove, Indiana • Boston, Massachusetts + 2 more

Conditions: Bladder Cancer, Ta/T1, CIS
Interventions: nadofaragene firadenovec; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Little Rock, Arkansas • Atlanta, Georgia

Conditions: Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions: Oral Encochleated Amphotericin B (CAMB), Fluconazole; Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension
Interventions: Trimethaphan, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Major Depressive Disorder
Interventions: agomelatine, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 78
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: CP-751,871, paclitaxel, carboplatin, erlotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 26
States / cities: Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more

Conditions: Defibrillators, Implantable, Tachycardia, Ventricular
Interventions: Ablation, Amiodarone; Procedure · Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 19 Years to 84 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Chicago, Illinois • Rochester, Minnesota • Philadelphia, Pennsylvania + 2 more

Conditions: Solid Tumors
Interventions: Iniparib (SAR240550/BSI-201), Carboplatin, Doxorubicin HCL liposome injection, Gemcitabine, Irinotecan, Paclitaxel, Topotecan; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Santa Maria, California • Vallejo, California + 25 more

Conditions: Non-inflammatory Degenerative Joint Disease
Interventions: ASR™-XL Modular Acetabular Cup System, Pinnacle™ acetabular shell; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 8
States / cities: Rancho Mirage, California • Cumming, Georgia • Morton Grove, Illinois + 5 more

Conditions: Endometrial Cancer
Interventions: carboplatin, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: GK1-399 (formerly TTP399), Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • Chula Vista, California • DeLand, Florida + 8 more

Conditions: Metastatic NSCLC
Interventions: GRN-1201 + Pembrolizumab; Biological
Lead sponsor: BrightPath Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Orlando, Florida + 7 more

Conditions: High Grade Gliomas, Brain Tumors
Interventions: adjuvant therapy, Temozolomide, Valproic Acid, Radiation therapy; Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania • Richmond, Virginia

Conditions: Multiple Sclerosis
Interventions: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Drug
Lead sponsor: PDL BioPharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 30
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 26 more

Conditions: Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions: Not listed
Lead sponsor: The Parkinson Study Group; Network
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hemophilia A
Interventions: Recombinant Protein-Free Factor VIII (rAHF-PFM); Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Lipoaspiration with Local anesthesia; Procedure
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Cheek, Wrinkle
Interventions: Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 21 Years and older
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 13
States / cities: Scottsdale, Arizona • Encino, California • Redondo Beach, California + 9 more

Search by objective public record fields.

Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study

Multi-Center Pilot Study of Cutera truSculpt Device

Evaluate the Continued Safety and Performance of the Foot and Ankle Products

Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic

Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Multi-Center Comparative Trial of the ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Diagnostic and Prognostic Biomarkers in Parkinson Disease

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

Open Label Extension for 43USSA1812